What are the major opportunities in the Neurodegenerative Disease market? What are the strategies for the Neurodegenerative Disease market?

For detailed insights on the major opportunities and strategies in the Neurodegenerative Disease market, Read More

How does the Neurodegenerative Disease market relate to the overall economy and other similar markets?

For detailed insights on Neurodegenerative Disease's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Neurodegenerative Disease market growth? SWOT analysis of the Neurodegenerative Disease market.

For detailed insights on the key dynamics influencing the Neurodegenerative Disease market growth and SWOT analysis of the Neurodegenerative Disease industry, Read More

Global Neurodegenerative Disease Market Report 2025

Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Neurodegenerative Disease Global Market Report 2025

Name: Neurodegenerative Disease Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Disease Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis), By Drug Type (N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types), By Route of Administration (Oral, Injectable, Transdermal, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), By End-User (Hospital, Retail, Online) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Neurodegenerative Disease Market?

Neurodegenerative disease refers to a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, including the brain and spinal cord. Its primary goal is to understand, diagnose, and treat these conditions through advancements in biotechnology, pharmaceuticals, and medical technology. This field aims to slow disease progression, improve patient outcomes, and reduce the healthcare burden. It supports aging populations, enhances neurological care, and contributes to a sustainable, technology-driven healthcare system.

The main types of neurodegenerative diseases are parkinson's disease, alzheimer's disease, Multiple Sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Parkinson's disease is a progressive neurological disorder that affects movement control due to the loss of dopamine-producing brain cells. These conditions are treated using various types of drugs such as N-methyl-D-aspartate (NMDA) receptor antagonists, cholinesterase inhibitors, dopamine agonists, and immunomodulatory drugs. The routes of administration include oral, injectable, transdermal, and other methods. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. The key end-users are hospitals, retail providers, and online platforms.

Neurodegenerative Disease Market Size and growth rate 2025 to 2029: Graph

What Is The Neurodegenerative Disease Market Size 2025 And Growth Rate?

The neurodegenerative disease market size has grown strongly in recent years. It will grow from $52.3 billion in 2024 to $57.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing diagnostic capabilities, rising demand for symptomatic treatments, a rise in clinical trial activities, increasing public-private partnerships, and a rising burden of unmet medical needs.

What Is The Neurodegenerative Disease Market Growth Forecast?

The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $81.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing advancements in gene and cell therapy, increasing adoption of digital biomarkers, a rise in precision medicine approaches, a growing pipeline of disease-modifying drugs, and increasing use of artificial intelligence in neurology. Major trends in the forecast period include advancements in neuroimaging techniques, advanced drug delivery systems for brain targeting, the development of personalized treatment strategies, innovation in biomarker discovery, and advancements in gene editing technologies.

Book your 30 minutes free consultation with our research experts

How Is The Neurodegenerative Disease Market Segmented?

The neurodegenerative disease market covered in this report is segmented –

1) By Disease Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis

2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types

3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospital, Retail, Online

Subsegment:

1) By Parkinson's Disease: Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-Onset Parkinson's Disease, Parkinsonism

2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease, Familial Alzheimer's Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype

3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)

4) By Huntington's Disease: Adult-Onset Huntington's Disease, Juvenile Huntington's Disease

5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)

What Is Driving The Neurodegenerative Disease Market? The Increase In Research And Clinical Trials Driving The Growth Of The Market Due To Enhanced Drug Evaluation And Development

The increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market going forward. Clinical trials refer to research studies conducted with human participants to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in research and clinical trials is primarily driven by the rising demand for new treatments to address evolving healthcare needs and improve patient outcomes. Clinical trials support neurodegenerative disease research by providing critical data on the safety and effectiveness of new treatments, helping to advance therapeutic development and improve patient outcomes. For instance, in November 2023, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, the total number of industry clinical trials initiated annually in the UK increased slightly by 4.3%, rising from 394 trials in 2021 to 411 in 2022. Therefore, the increase in research and clinical trials is expected to propel the growth of the neurodegenerative disease market.

Who Are The Major Players In The Global Neurodegenerative Disease Market?

Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.

What Are The Key Trends Of The Global Neurodegenerative Disease Market? Emergence Of Real-time Personalized Treatments Enhancing Patient Outcomes

Major companies operating in the neurodegenerative disease market are focusing on developing innovative products such as next-generation adaptive Deep Brain Stimulation (aDBS) systems, aiming to improve treatment precision, enhance disease-modifying effects, and increase patient quality of life. Next generation adaptive deep brain stimulation (aDBS) systems are advanced neurostimulation devices designed to provide real-time, personalized treatment for Parkinson's disease by dynamically adjusting stimulation parameters based on neural feedback, optimizing therapeutic effects, and minimizing side effects for improved patient outcomes. For instance, in February 2025, Medtronic, a US-based medical technology company, received approval from the U.S. Food and Drug Administration (USFDA) for the world's first adaptive deep brain stimulation (aDBS) system for Parkinson's disease. This approval pertains to the premarket approval (PMA) application for the Percept RC neurostimulator with BrainSense technology, which automatically adjusts therapy in response to a patient's brain signals. The system is clinically validated to provide symptom relief for advanced Parkinson's disease patients and represents a significant advancement in personalized neuromodulation therapies.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Neurodegenerative Disease Market? AbbVie Acquires Aliada Therapeutics To Strengthen Neurodegenerative Disease Pipeline

In December 2024, AbbVie, a US-based biopharmaceutical company, acquired Aliada Therapeutics for an undisclosed amount. With this acquisition, AbbVie aims to advance potentially disease-modifying therapies for Alzheimer’s disease and strengthen its neuroscience pipeline by leveraging Aliada’s novel blood-brain barrier-crossing drug delivery platform. Aliada Therapeutics is a US-based company that develops precision medicines for neurological conditions.

What Is The Regional Outlook For The Global Neurodegenerative Disease Market?

North America was the largest region in the neurodegenerative disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurodegenerative disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurodegenerative Disease Market?

The neurodegenerative disease market consists of revenues earned by entities through services such as biotechnology research, pharmaceutical development, diagnostic solutions, medical technologies, and patient care advancements aimed at understanding, diagnosing, and treating neurodegenerative conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodegenerative disease market also includes sales of pharmaceuticals, biotechnology treatments, medical devices, and diagnostic tools aimed at managing and treating neurodegenerative conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neurodegenerative Disease Industry?

The neurodegenerative diseases market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative diseases market statistics, including the neurodegenerative diseases industry global market size, regional shares, competitors with the neurodegenerative diseases market share, detailed neurodegenerative diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the neurodegenerative diseases industry. This neurodegenerative diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abhilash Pyata

Neurodegenerative Disease Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$57.23 billion
Revenue Forecast In 2034	$81.23 billion
Growth Rate	CAGR of 9.2% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The neurodegenerative disease market covered in this report is segmented – 1) By Disease Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis 2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types 3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 5) By End-User: Hospital, Retail, Online Subsegment: 1) By Parkinson's Disease: Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-Onset Parkinson's Disease, Parkinsonism 2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease, Familial Alzheimer's Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype 3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS) 4) By Huntington's Disease: Adult-Onset Huntington's Disease, Juvenile Huntington's Disease 5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Neurodegenerative Disease Market Characteristics

3. Neurodegenerative Disease Market Trends And Strategies

4. Neurodegenerative Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurodegenerative Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Neurodegenerative Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Neurodegenerative Disease Market Growth Rate Analysis

5.4. Global Neurodegenerative Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Neurodegenerative Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Neurodegenerative Disease Total Addressable Market (TAM)

6. Neurodegenerative Disease Market Segmentation

6.1. Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parkinson's Disease

Alzheimer's Disease

Multiple Sclerosis

Huntington Disease

Amyotrophic Lateral Sclerosis

6.2. Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

N-methyl-D-aspartate Receptor antagonists

Cholinesterase Inhibitors

Dopamine Agonists

Immunomodulatory Drugs

Acetylcholinesterase (AChE) Inhibitors

Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor

Catechol-O-Methyltransferase (COMT) Inhibitor

Selective Serotonin Reuptake Inhibitor (SSRIs)

Other Drug Types

6.3. Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Injectable

Transdermal

Other Routes Of Administration

6.4. Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

6.5. Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital

Retail

Online

6.6. Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Idiopathic Parkinson's Disease

Familial Parkinson's Disease

Early-Onset Parkinson's Disease

Parkinsonism

6.7. Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Early-Onset Alzheimer's Disease

Late-Onset Alzheimer's Disease

Familial Alzheimer's Disease (FAD)

Inflammatory Subtype

Non-Inflammatory Subtype

Cortical Subtype

6.8. Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Clinically Isolated Syndrome (CIS)

Relapsing-Remitting MS (RRMS)

Secondary Progressive MS (SPMS)

Primary Progressive MS (PPMS)

Progressive-Relapsing MS (PRMS)

6.9. Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Adult-Onset Huntington's Disease

Juvenile Huntington's Disease

6.10. Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Classical ALS

Limb-Onset ALS

Bulbar-Onset ALS

Respiratory-Onset ALS

Primary Lateral Sclerosis (PLS)

Progressive Muscular Atrophy (PMA)

Juvenile ALS

ALS-Parkinsonism-Dementia Complex (ALS-PDC)

7. Neurodegenerative Disease Market Regional And Country Analysis

7.1. Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurodegenerative Disease Market

8.1. Asia-Pacific Neurodegenerative Disease Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurodegenerative Disease Market

9.1. China Neurodegenerative Disease Market Overview

9.2. China Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurodegenerative Disease Market

10.1. India Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurodegenerative Disease Market

11.1. Japan Neurodegenerative Disease Market Overview

11.2. Japan Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurodegenerative Disease Market

12.1. Australia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurodegenerative Disease Market

13.1. Indonesia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurodegenerative Disease Market

14.1. South Korea Neurodegenerative Disease Market Overview

14.2. South Korea Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurodegenerative Disease Market

15.1. Western Europe Neurodegenerative Disease Market Overview

15.2. Western Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurodegenerative Disease Market

16.1. UK Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurodegenerative Disease Market

17.1. Germany Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurodegenerative Disease Market

18.1. France Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurodegenerative Disease Market

19.1. Italy Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurodegenerative Disease Market

20.1. Spain Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurodegenerative Disease Market

21.1. Eastern Europe Neurodegenerative Disease Market Overview

21.2. Eastern Europe Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurodegenerative Disease Market

22.1. Russia Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurodegenerative Disease Market

23.1. North America Neurodegenerative Disease Market Overview

23.2. North America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurodegenerative Disease Market

24.1. USA Neurodegenerative Disease Market Overview

24.2. USA Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurodegenerative Disease Market

25.1. Canada Neurodegenerative Disease Market Overview

25.2. Canada Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurodegenerative Disease Market

26.1. South America Neurodegenerative Disease Market Overview

26.2. South America Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurodegenerative Disease Market

27.1. Brazil Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurodegenerative Disease Market

28.1. Middle East Neurodegenerative Disease Market Overview

28.2. Middle East Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurodegenerative Disease Market

29.1. Africa Neurodegenerative Disease Market Overview

29.2. Africa Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurodegenerative Disease Market Competitive Landscape And Company Profiles

30.1. Neurodegenerative Disease Market Competitive Landscape

30.2. Neurodegenerative Disease Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Neurodegenerative Disease Market Other Major And Innovative Companies

31.1. Novartis AG

31.2. Takeda Pharmaceutical Company Limited

31.3. Eli Lilly and Company

31.4. Merck & Co. Inc.

31.5. Biogen Inc.

31.6. Neurocrine Biosciences Inc.

31.7. Alnylam Pharmaceuticals Inc.

31.8. Ionis Pharmaceuticals Inc.

31.9. Cassava Sciences Inc.

31.10. Denali Therapeutics Inc.

31.11. Voyager Therapeutics Inc.

31.12. AC Immune SA

31.13. Amylyx Pharmaceuticals Inc.

31.14. Sage Therapeutics Inc.

31.15. Alzheon Inc.

32. Global Neurodegenerative Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disease Market

34. Recent Developments In The Neurodegenerative Disease Market

35. Neurodegenerative Disease Market High Potential Countries, Segments and Strategies

35.1 Neurodegenerative Disease Market In 2029 - Countries Offering Most New Opportunities

35.2 Neurodegenerative Disease Market In 2029 - Segments Offering Most New Opportunities

35.3 Neurodegenerative Disease Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: China, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: India, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Japan, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Australia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Indonesia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: South Korea, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Western Europe, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: UK, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Germany, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: France, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Italy, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Spain, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Russia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: North America, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: USA, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Canada, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: South America, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Brazil, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Middle East, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Africa, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 81: Pfizer Inc. Financial Performance

Table 82: Johnson & Johnson Financial Performance

Table 83: F. Hoffmann-La Roche Ltd Financial Performance

Table 84: AbbVie Inc. Financial Performance

Table 85: Sanofi S.A. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Neurodegenerative Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Neurodegenerative Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Neurodegenerative Disease Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Neurodegenerative Disease Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Neurodegenerative Disease Market, Sub-Segmentation Of Multiple Sclerosis (MS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Neurodegenerative Disease Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Neurodegenerative Disease Market, Sub-Segmentation Of Amyotrophic Lateral Sclerosis (ALS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Neurodegenerative Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Global Neurodegenerative Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Asia-Pacific, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: China, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: India, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Japan, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Australia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Indonesia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: South Korea, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Western Europe, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: UK, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Germany, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: France, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Italy, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Spain, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Eastern Europe, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Russia, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: North America, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: USA, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Canada, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: South America, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Brazil, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Middle East, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Neurodegenerative Disease Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Neurodegenerative Disease Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Africa, Neurodegenerative Disease Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 81: Pfizer Inc. Financial Performance

Figure 82: Johnson & Johnson Financial Performance

Figure 83: F. Hoffmann-La Roche Ltd Financial Performance

Figure 84: AbbVie Inc. Financial Performance

Figure 85: Sanofi S.A. Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Brain Health Supplements Global Market Report 2025 – By Product (Natural Molecules, Herbal Extract, Vitamins and Minerals), By Supplement Form (Tablets, Capsules, Liquid), By Distribution (Supermarket and Hypermarket, Dr...

Rare Neurological Disease Treatment Global Market Report 2025 – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies), By Mode Of A...

Degenerative Disc Disease Treatment Global Market Report 2025 – By Type (Conventional Drugs, Novel Therapies), By Route Of Administration (Oral, Injectable), By End User (Hospitals, Ambulatory Surgical Centers, Orthopedi...

Neurological Disorder Drugs Global Market Report 2025 – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), B...

Neurofibromatosis Treatment Global Market Report 2025 – By Type (Neurofibromatosis 1 (NF–, Neurofibromatosis 2 (NF, Schwannomatosis), By Treatment (Medications, Surgery, Radiation Therapy, Other Treatments), By End-Users...

Neurological Biomarkers Global Market Report 2025 – By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products), By Application (Alzheimer’s Disease, Parkinson’s Disea...

Generic Central Nervous System Drugs Global Market Report 2025 – By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types), By Drug C...

Frequently Asked Questions

What is the definition of the Neurodegenerative Disease market?

How will the Neurodegenerative Disease market drivers and restraints affect the market dynamics? What forces will shape the Neurodegenerative Disease industry going forward?

The Neurodegenerative Disease market major growth driver - The Increase In Research And Clinical Trials Driving The Growth Of The Market Due To Enhanced Drug Evaluation And Development. For further insights on the Neurodegenerative Disease market, request a sample here

What is the forecast market size or the forecast market value of the Neurodegenerative Disease market?

The Neurodegenerative Disease market size has grown strongly in recent years. The neurodegenerative disease market size has grown strongly in recent years. It will grow from $52.3 billion in 2024 to $57.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing diagnostic capabilities, rising demand for symptomatic treatments, a rise in clinical trial activities, increasing public-private partnerships, and a rising burden of unmet medical needs. The neurodegenerative disease market size is expected to see strong growth in the next few years. It will grow to $81.23 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing advancements in gene and cell therapy, increasing adoption of digital biomarkers, a rise in precision medicine approaches, a growing pipeline of disease-modifying drugs, and increasing use of artificial intelligence in neurology. Major trends in the forecast period include advancements in neuroimaging techniques, advanced drug delivery systems for brain targeting, the development of personalized treatment strategies, innovation in biomarker discovery, and advancements in gene editing technologies. For further insights on the Neurodegenerative Disease market, request a sample here

How is the Neurodegenerative Disease market segmented?

The neurodegenerative disease market covered in this report is segmented –
1) By Disease Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospital, Retail, Online

Subsegment:
1) By Parkinson's Disease: Idiopathic Parkinson's Disease, Familial Parkinson's Disease, Early-Onset Parkinson's Disease, Parkinsonism
2) By Alzheimer's Disease: Early-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease, Familial Alzheimer's Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
4) By Huntington's Disease: Adult-Onset Huntington's Disease, Juvenile Huntington's Disease
5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC) For further insights on the Neurodegenerative Disease market, request a sample here

Which region has the largest share of the Neurodegenerative Disease market? What are the other regions covered in the report?

Who are the major players in the Neurodegenerative Disease market?

What are the key trends in the Neurodegenerative Disease market?

Major trends in the Neurodegenerative Disease market include Emergence Of Real-time Personalized Treatments Enhancing Patient Outcomes. For further insights on the Neurodegenerative Disease market, request a sample here.